Healthy Non-smokers, Current Smokers, COPD Patients
Conditions
Brief summary
The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).
Interventions
PROCEDURESpirometry
PROCEDUREExhaled Nitric Oxide and Carbon Monoxide
PROCEDUREExhaled Breath Condensate
PROCEDUREInduced Sputum
PROCEDURECT Scan
PROCEDUREBlood test
PROCEDURESt Georges Questionnaire
PROCEDUREBodypletysmography
Sponsors
AstraZeneca
Imperial College London
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy non-smokers * FEV1 \>80% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists Current smokers * FEV1 no less than 80% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists * Smoking history of \> 10 pack-years Moderate COPD * FEV1 40-59% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists * Smoking history of \> 10 pack-years\*\* Severe COPD * FEV1 \<40% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists * Smoking history of \> 10 pack-years
Exclusion criteria
* FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists * Asthma * unstable disease (FEV1 \<35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.
Countries
United Kingdom
Outcome results
None listed